CO2023005482A2 - Anticuerpo anti-epha4 - Google Patents
Anticuerpo anti-epha4Info
- Publication number
- CO2023005482A2 CO2023005482A2 CONC2023/0005482A CO2023005482A CO2023005482A2 CO 2023005482 A2 CO2023005482 A2 CO 2023005482A2 CO 2023005482 A CO2023005482 A CO 2023005482A CO 2023005482 A2 CO2023005482 A2 CO 2023005482A2
- Authority
- CO
- Colombia
- Prior art keywords
- seq
- heavy chain
- light chain
- epha4
- cdr2
- Prior art date
Links
- 102000021727 EphA4 Receptor Human genes 0.000 abstract 2
- 108010055179 EphA4 Receptor Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporciona un anticuerpo anti-EphA4 que puede unirse a EphA4 y potenciar la escisión de EphA4, y una composición farmacéutica que comprende el anticuerpo como un principio activo. El anticuerpo anti-EphA4 comprende una cadena pesada que comprende una CDR1 de cadena pesada de SEQ ID NO: 30; una CDR2 de cadena pesada de SEQ ID NO: 31; y una CDR3 de cadena pesada de SEQ ID NO: 32; y una cadena ligera que comprende una CDR1 de cadena ligera de SEQ ID NO: 33; una CDR2 de cadena ligera de SEQ ID NO: 34; y una CDR3 de cadena ligera de SEQ ID NO: 35, o una cadena pesada que comprende una CDR1 de cadena pesada de SEQ ID NO: 42; una CDR2 de cadena pesada de SEQ ID NO: 31; y una CDR3 de cadena pesada de SEQ ID NO: 43; y una cadena ligera que comprende una CDR1 de cadena ligera de SEQ ID NO: 44; una CDR2 de cadena ligera de SEQ ID NO: 34; y una CDR3 de cadena ligera de SEQ ID NO: 35.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020214958 | 2020-12-24 | ||
| PCT/JP2021/047534 WO2022138708A1 (ja) | 2020-12-24 | 2021-12-22 | 抗ＥｐｈＡ４抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023005482A2 true CO2023005482A2 (es) | 2023-05-19 |
Family
ID=82157006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0005482A CO2023005482A2 (es) | 2020-12-24 | 2023-04-28 | Anticuerpo anti-epha4 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230357386A1 (es) |
| EP (1) | EP4269588A1 (es) |
| JP (1) | JPWO2022138708A1 (es) |
| KR (1) | KR20230123923A (es) |
| CN (1) | CN116528899A (es) |
| AR (1) | AR124467A1 (es) |
| AU (1) | AU2021410893A1 (es) |
| CA (1) | CA3192342A1 (es) |
| CL (1) | CL2023001651A1 (es) |
| CO (1) | CO2023005482A2 (es) |
| IL (1) | IL303223A (es) |
| MX (1) | MX2023004850A (es) |
| TW (1) | TW202241949A (es) |
| WO (1) | WO2022138708A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| US8865426B2 (en) * | 2010-12-17 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| EP3473271B1 (en) | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
| AU2016319433A1 (en) * | 2015-09-08 | 2018-01-18 | Eisai R&D Management Co., Ltd. | Anti-EphA4 antibody |
-
2021
- 2021-12-22 JP JP2022571542A patent/JPWO2022138708A1/ja active Pending
- 2021-12-22 CA CA3192342A patent/CA3192342A1/en active Pending
- 2021-12-22 TW TW110148257A patent/TW202241949A/zh unknown
- 2021-12-22 AU AU2021410893A patent/AU2021410893A1/en active Pending
- 2021-12-22 MX MX2023004850A patent/MX2023004850A/es unknown
- 2021-12-22 KR KR1020237013988A patent/KR20230123923A/ko unknown
- 2021-12-22 IL IL303223A patent/IL303223A/en unknown
- 2021-12-22 US US18/027,413 patent/US20230357386A1/en active Pending
- 2021-12-22 CN CN202180081671.3A patent/CN116528899A/zh active Pending
- 2021-12-22 WO PCT/JP2021/047534 patent/WO2022138708A1/ja active Application Filing
- 2021-12-22 EP EP21910848.7A patent/EP4269588A1/en active Pending
- 2021-12-22 AR ARP210103617A patent/AR124467A1/es unknown
-
2023
- 2023-04-28 CO CONC2023/0005482A patent/CO2023005482A2/es unknown
- 2023-06-07 CL CL2023001651A patent/CL2023001651A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022138708A1 (es) | 2022-06-30 |
| WO2022138708A1 (ja) | 2022-06-30 |
| KR20230123923A (ko) | 2023-08-24 |
| MX2023004850A (es) | 2023-05-10 |
| IL303223A (en) | 2023-07-01 |
| CL2023001651A1 (es) | 2023-12-15 |
| US20230357386A1 (en) | 2023-11-09 |
| CN116528899A (zh) | 2023-08-01 |
| AU2021410893A1 (en) | 2023-06-08 |
| EP4269588A1 (en) | 2023-11-01 |
| AR124467A1 (es) | 2023-03-29 |
| TW202241949A (zh) | 2022-11-01 |
| CA3192342A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| CL2020001579A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) | |
| ECSP20014523A (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco | |
| CO2019009680A2 (es) | Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| CO2019006565A2 (es) | Novedoso conjugado de amanitina | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR091703A1 (es) | Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22 | |
| RS53924B1 (en) | NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| CR10308A (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos |